海角视频

Oops.

Our website is temporarily unavailable in your location.

We are working hard to get it back online.

PRIVACY
Enterprise

QuantuMDx seals significant deal with Menarini to distribute pioneering testing platform

CEO Jonathan O’Halloran said the agreement marks a significant commercial step for QuantuMDx

The Q-POC device developed by Newcastle company QuantuMDx(Image: QuantuMDx)

Tyneside health tech firm QuantuMDx has sealed a significant deal with an Italian firm to distribute its portable Covid, flu and respiratory disease testing system in the 海角视频 and France.

Earlier this year, the Newcastle company - which last year secured £15m venture capital investment - revealed its latest Q-POC respiratory panel test which can also detect Covid and other infectious diseases. The team had developed a new test to include the most up to date information on sequences of SARS-CoV-2, Flu A and Flu B & RSV viruses. Respiratory panel tests detect pathogens in the lungs, nose and throat.

Now the diagnostic specialist has announced an agreement which will see Florence-based Menarini market, sell and service Q-POC, QuantuMDx’s SARS- CoV-2 assay and its new test which the company launched in June. The firm said the deal, agreed for an undisclosed value, marks a significant commercial step for QuantuMDx. It said it will ramp up commercial sales of the platform with the mission to limit the fast spread of Covid and other respiratory diseases.

Read more: Motor insurer creates 150 Tyneside jobs

CEO Jonathan O’Halloran said that, winter fast approaching and Covid and respiratory diseases on the rise again, there is a strong need for rapid high quality PCR testing that can accurately diagnose and differentiate between highly prevalent infectious diseases. The five-year agreement will initially cover distribution to the 海角视频 and France, with the scope to expand to other markets.

Mr O’Halloran said: “This agreement with Menarini is a significant commercial step for QuantuMDx. Not only does Menarini have a vast global network, but their specific in-country knowledge and presence across Europe, and beyond, means they are an excellent partner for us. The agreement will allow us to further accelerate commercial sales of Q- POC™, bringing our Point-of-Need multiplex molecular diagnostics platform to clinical and non-clinical settings in a host of new markets.

Jonathan O’Halloran, chief executive officer at QuantuMDx Group(Image: publicity handover from QuantuMDx)

“I look forward to working closely with Menarini on what I am confident will be a very successful partnership.”

Fabio Piazzalunga, global head at Menarini Diagnostics, said: “The recent pandemic has highlighted the importance of being able to accurately, and rapidly, diagnose infectious diseases. QuantuMDx’s Q-POC platform, which can provide results in approximately 30 minutes, will allow healthcare professionals to make informed treatment decisions and slow the risk of transmission.